CCL18 and pancreatic ductal adenocarcinoma: For human pancreatic ductal adenocarcinoma (PDAC), serum CCL18 is a potential biomarker of diagnosis and prognosis and have been found promoting the epithelial–mesenchymal transition (EMT), invasion, and migration of pancreatic cancer cells [28].